The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: Implications for clinical use

Epilepsia

Volumn 53, Issue 3, 2012, Pages 425-436

  Large, Charles H ^a   Sokal, David M ^a   Nehlig, Astrid ^b   Gunthorpe, Martin J ^c   Sankar, Raman ^d   Crean, Christopher S ^e   Vanlandingham, Kevan E ^f   White, H Steve ^g  

^a Autifony Srl ^*  (Italy)

^b INSERM   (France)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Valeant Pharmaceuticals North America LLC   (United States)

^f GLAXOSMITHKLINE   (United States)

^g UNIVERSITY OF UTAH   (United States)

Author keywords

Antiepileptic drug; Epilepsy; K v7; KCNQ; Potassium channel; Preclinical models; Refractory epilepsy; Seizure

Indexed keywords

4 AMINOPYRIDINE; BICUCULLINE; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; PENTETRAZOLE; PHENYTOIN; POTASSIUM CHANNEL KCNQ; RETIGABINE; TOPIRAMATE; VALPROIC ACID;

ABSENCE; ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; BRAIN TISSUE; DISEASE MODEL; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DRUG USE; EPILEPSY; EPILEPTIC DISCHARGE; EPILEPTIC STATE; EPILEPTOGENESIS; FOCAL EPILEPSY; GENERALIZED EPILEPSY; GENETIC MODEL; GRAND MAL SEIZURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; NERVE CELL EXCITABILITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TEMPORAL LOBE EPILEPSY; TONIC CLONIC SEIZURE;

ANIMALS; ANTICONVULSANTS; CARBAMATES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; EPILEPSY; HUMANS; KCNQ POTASSIUM CHANNELS; NEURONS; PHENYLENEDIAMINES; TREATMENT OUTCOME;

EID: 84857655167     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2011.03364.x     Document Type: Review

References (91)

1. Armand V, Rundfeldt C, Heinemann U,. (1999) Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol 359: 33-39. (Pubitemid 29142567)
2. Armand V, Rundfeldt C, Heinemann U,. (2000) Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 41: 28-33. (Pubitemid 30036851)
3. Barton ME, Klein BD, Wolf HH, White HS,. (2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47: 217-227. (Pubitemid 34008465)
4. Bernasconi N, Natsume J, Bernasconi A,. (2005) Progression in temporal lobe epilepsy: differential trophy in mesial temporal structures. Neurology 65: 223-228. (Pubitemid 41022365)
5. Bernhardt BC, Rozen DA, Worsley KJ, Evans AC, Bernasconi N, Bernasconi A,. (2009a) Thalamo-cortical network pathology in idiopathic generalized epilepsy: insights from MRI-based morphometric correlation analysis. Neuroimage 46: 373-381.
6. Bernhardt BC, Worsley KJ, Kim H, Evans AC, Bernasconi A, Bernasconi N,. (2009b) Longitudinal and cross-sectional analysis of atrophy in pharmacoresistant temporal lobe epilepsy. Neurology 72: 1747-1754.
7. Bertram E,. (2007) The relevance of kindling for human epilepsy. Epilepsia 48 (Suppl. 2): 65-74. (Pubitemid 46850004)
8. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS,. (2009) Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 83: 1-43.
9. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, Steinlein OK,. (1998) A potassium channel mutation in neonatal human epilepsy. Science 279: 403-406. (Pubitemid 28063379)
10. Boscia F, Annunziato L, Taglialatela M,. (2006) Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharmacology 51: 283-294. (Pubitemid 44061890)
11. Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, Nohria V, Mansbach H,; RESTORE 2 Study Group. (2010) Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 75: 1817-1824.
12. Buckmaster PS, Dudek FE,. (1997) Neuron loss, granule cell axon reorganization, and functional changes in the dentate gyrus of epileptic kainate-treated rats. J Comp Neurol 385: 385-404. (Pubitemid 27417924)
13. Buono RJ, Lohoff FW, Sander T, Sperling MR, O'Connor MJ, Dlugos DJ, Ryan SG, Golden GT, Zhao H, Scattergood TM, Berrettini WH, Ferraro TN,. (2004) Association between variation in the human KCNJ10 potassium ion channel gene and seizure susceptibility. Epilepsy Res 58: 175-183. (Pubitemid 38553953)
14. Charlier C, Singh NA, Ryan SG, Lewis TB, Reus BE, Leach RJ, Leppert M,. (1998) A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 18: 53-55. (Pubitemid 28027879)
15. Crunelli V, Leresche N,. (2002) Childhood absence epilepsy: genes, channels, neurons and networks. Nat Rev Neurosci 3: 371-382. (Pubitemid 135706634)
16. Czuczwar P, Wojtak A, Cioczek-Czuczwar A, Parada-Turska J, Maciejewski R, Czuczwar SJ,. (2010) Retigabine: the newer potential antiepileptic drug. Pharmacol Rep 62: 211-219.
17. Dailey JW, Cheong JH, Ko KH, Adams-Curtis LE, Jobe PC,. (1995) Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response. Neurosci Lett 195: 77-80.
18. Danober L, Deransart C, Depaulis A, Vergnes M, Marescaux C,. (1998) Pathophysiological mechanisms of genetic absence epilepsy in the rat. Prog Neurobiol 55: 27-57. (Pubitemid 28231101)
19. De Sarro G, Di Paola ED, Conte G, Pasculli MP, De Sarro A,. (2001) Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. Naunyn Schmiedebergs Arch Pharmacol 363: 330-336. (Pubitemid 32186532)
20. Dost R, Rundfeldt C,. (2000) The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation. Epilepsy Res 38: 53-66. (Pubitemid 30055316)
21. Ferraro TN, Golden GT, Dahl JP, Smith GG, Schwebel CL, MacDonald R, Lohoff FW, Berrettini WH, Buono RJ,. (2007) Analysis of a quantitative trait locus for seizure susceptibility in mice using bacterial artificial chromosome-mediated gene transfer. Epilepsia 48: 1667-1677. (Pubitemid 47352866)
22. Frankel WN,. (2009) Genetics of complex neurological disease: challenges and opportunities for modeling epilepsy in mice and rats. Trends Genet 25: 361-367.
23. French JA, Abou-Khalil BW, Leroy RF, Yacubian EMT, Shin P, Hall S, Mansbach H, Nohria V,; on behalf of the RESTORE 1/Study 301 Investigators. (2011) Randomized double-blind placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 76: 1555-1563.
24. Fuerst D, Shah J, Shah A, Watson C,. (2003) Hippocampal sclerosis is a progressive disorder: a longitudinal volumetric MRI study. Ann Neurol 53: 413-416. (Pubitemid 36258649)
25. Geiger J, Weber YG, Landwehrmeyer B, Sommer C, Lerche H,. (2006) Immunohistochemical analysis of KCNQ3 potassium channels in mouse brain. Neurosci Lett 400: 101-104.
26. Grabenstatter HL, Dudek FE,. (2008) A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 49: 1787-1794.
27. Grabenstatter HL, Ferraro DJ, Williams PA, Chapman PL, Dudek FE,. (2005) Use of chronic epilepsy models in antiepileptic drug discovery: the effect of topiramate on spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 46: 8-14. (Pubitemid 40179927)
28. Grabenstatter HL, Clark S, Dudek FE,. (2007) Anticonvulsant effects of carbamazepine on spontaneous seizures in rats with kainate-induced epilepsy: comparison of intraperitoneal injections with drug-in-food protocols. Epilepsia 48: 2287-2295. (Pubitemid 350243413)
29. Gunthorpe MJ, Large CH, Sankar R,. (2012) The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 53: 412-424.
30. Hall CS,. (1947) Genetic differences in fatal audiogenic seizures between two inbred strains of mouse. J Hered 38: 2-6.
31. Hughes JR,. (2009) Some correlations between the electroencephalogram and normal and pathologic mental process. Epilepsy Behav 14: 452-453.
32. Kasten MR, Rudy B, Anderson MP,. (2007) Differential regulation of action potential firing in adult murine thalamocortical neurons by Kv3.2, Kv1, and SK potassium and N-type calcium channels. J Physiol 584: 565-582. (Pubitemid 47578339)
33. Kohling R, Lucke A, Straub H, Speckmann EJ, Tuxhorn I, Wolf P, Pannek H, Oppel F,. (1998) Spontaneous sharp waves in human neocortical slices excised from epileptic patients. Brain 121: 1073-1087. (Pubitemid 28256981)
34. Kotloski R, Lynch M, Lauersdorf S, Sutula T,. (2002) Repeated brief seizures induce progressive hippocampal neuron loss and memory deficits. Prog Brain Res 135: 95-110. (Pubitemid 35461009)
35. Kwan P, Brodie MJ,. (2006) Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 6: 397-406.
36. Large CH, Kalinichev M, Lucas A, Carignani C, Bradford A, Garbati N, Sartori I, Austin NE, Ruffo A, Jones DN, Alvaro G, Read KD,. (2009) The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res 85: 96-106.
37. Löscher W,. (2002) Animal models of drug-resistant epilepsy. Novartis Found Symp 243: 149-159.
38. Lothman EW, Hatlelid JM, Zorumski CF, Conry JA, Moon PF, Perlin JB,. (1985) Kindling with rapidly recurring hippocampal seizures. Brain Res 360: 83-91. (Pubitemid 16171004)
39. Luszczki JJ, Wu JZ, Raszewski G, Czuczwar SJ,. (2009) Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol 379: 163-179.
40. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA,. (2000) Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 58: 253-262. (Pubitemid 30497468)
41. Marescaux C, Micheletti G, Vergnes M, Depaulis A, Rumbach L, Warter JM,. (1984) A model of chronic spontaneous petit mal-like seizures in the rat: comparison with pentylenetetrazol-induced seizures. Epilepsia 25: 326-331. (Pubitemid 14121642)
42. Marescaux C, Vergnes M, Depaulis A,. (1992) Genetic absence epilepsy in rats from Strasbourg-a review. J Neural Transm Suppl 35: 37-69.
43. Mazarati A, Shin D, Auvin S, Sankar R,. (2007) Age-dependent effects of topiramate on the acquisition and the retention of rapid kindling. Epilepsia 48: 765-773. (Pubitemid 46587626)
44. Mazarati A, Wu J, Shin D, Kwon YS, Sankar R,. (2008) Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study. Epilepsia 49: 1777-1786.
45. McIntyre DC, Gilby KL,. (2009) Kindling as a model of human epilepsy. Can J Neurol Sci 36 (Suppl. 2): S33-S35.
46. Micheletti G, Vergnes M, Marescaux C, Reis J, Depaulis A, Rumbach L, Warter JM,. (1985) Antiepileptic drug evaluation in a new animal model: spontaneous petit mal epilepsy in the rat. Arzneimittelforschung 35: 483-485. (Pubitemid 15155409)
47. Mora G, Tapia R,. (2005) Effects of retigabine on the neurodegeneration and extracellular glutamate changes induced by 4-aminopyridine in rat hippocampus in vivo. Neurochem Res 30: 1557-1565. (Pubitemid 41813720)
48. Nadler JV,. (1981) Minireview. Kainic acid as a tool for the study of temporal lobe epilepsy. Life Sci 29: 2031-2042. (Pubitemid 12178982)
49. Nakayama J, Fu YH, Clark AM, Nakahara S, Hamano K, Iwasaki N, Matsui A, Arinami T, Ptacek LJ,. (2002) A nonsense mutation of the MASS1 gene in a family with febrile and afebrile seizures. Ann Neurol 52: 654-657. (Pubitemid 35246872)
50. Nissinen J, Pitkänen A,. (2007) Effect of antiepileptic drugs on spontaneous seizures in epileptic rats. Epilepsy Res 73: 181-191. (Pubitemid 46329332)
51. Otto JF, Kimball MM, Wilcox KS,. (2002) Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission. Mol Pharmacol 61: 921-927. (Pubitemid 34273173)
52. Otto JF, Yang Y, Frankel WN, Wilcox KS, White HS,. (2004) Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel. Epilepsia 45: 1009-1016. (Pubitemid 39238109)
53. Owen RT,. (2010) Ezogabine: a novel antiepileptic as adjunctive therapy for partial onset seizures. Drugs Today (Barc) 46: 815-822.
54. Pitkänen A, Lukasiuk K,. (2009) Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav 14 (Suppl. 1): 16-25.
55. Pitkänen A, Sutula TP,. (2002) Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 1: 173-181.
56. Pitkänen A, Kharatishvili I, Karhunen H, Lukasiuk K, Immonen R, Nairismagi J, Grohn O, Nissinen J,. (2007) Epileptogenesis in experimental models. Epilepsia 48 (Suppl. 2): 13-20. (Pubitemid 46849999)
57. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM,; on behalf of the 205 Study Group. (2007) Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 68: 1197-1204. (Pubitemid 46608467)
58. Postma T, Krupp E, Li XL, Post RM, Weiss SR,. (2000) Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy. Epilepsia 41: 1514-1521. (Pubitemid 32002723)
59. Reigel CE, Dailey JW, Jobe PC,. (1986) The genetically epilepsy-prone rat: an overview of seizure-prone characteristics and responsiveness to anticonvulsant drugs. Life Sci 39: 763-774.
60. Rekling JC,. (2003) Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation. Neurosci Lett 335: 167-170. (Pubitemid 36071626)
61. Remy S, Gabriel S, Urban BW, Dietrich D, Lehmann TN, Elger CE, Heinemann U, Beck H,. (2003) A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol 53: 469-479. (Pubitemid 36373258)
62. Robbins J,. (2001) KCNQ potassium channels: physiology, pathophysiology, and pharmacology. Pharmacol Ther 90: 1-19. (Pubitemid 32622837)
63. Roeloffs R, Wickenden AD, Crean C, Werness S, Naughton-Smith G, Stables J, McNamara JO, Ghodadra N, Rigdon GC,. (2008) In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models. J Pharmacol Exp Ther 326: 818-828.
64. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, Löscher W, Honack D, White HS, Wolf HH,. (1996) D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 23: 211-223. (Pubitemid 26176549)
65. Saganich MJ, Machado E, Rudy B,. (2001) Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain. J Neurosci 21: 4609-4624. (Pubitemid 32565620)
66. Sankar R, Wu J, Shin D, Mazarati A,. (2009) Retigabine inhibits rapid kindling epileptogenesis in rats through the activation of Kv7.2/7.3 channels. Epilepsia 50 (Suppl. 4): 88.
67. Sankar R, Auvin S, Kwon YS, Pineda E, Shin D, Mazarati A,. (2010) Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling. Epilepsia 51 (Suppl. 3): 39-42.
68. Schmidt B,. (2007) Clinical development of antiepileptic drugs in adults. Neurotherapeutics 4: 62-69. (Pubitemid 46127464)
69. Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, Jentsch TJ,. (2000) KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem 275: 24089-24095. (Pubitemid 30624700)
70. Seyfried J, Evert BO, Rundfeldt C, Schulz JB, Kovar KA, Klockgether T, Wullner U,. (2000) Flupirtine and retigabine prevent L-glutamate toxicity in rat pheochromocytoma PC 12 cells. Eur J Pharmacol 400: 155-166. (Pubitemid 30438722)
71. Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, Quattlebaum T, Murphy JV, McHarg ML, Gagnon D, Rosales TO, Peiffer A, Anderson VE, Leppert M,. (1998) A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 18: 25-29. (Pubitemid 28027874)
72. Skradski SL, Clark AM, Jiang H, White HS, Fu YH, Ptacek LJ,. (2001) A novel gene causing a mendelian audiogenic mouse epilepsy. Neuron 31: 537-544. (Pubitemid 32835109)
73. Sloviter RS,. (1991) Permanently altered hippocampal structure, excitability, and inhibition after experimental status epilepticus in the rat: the "dormant basket cell" hypothesis and its possible relevance to temporal lobe epilepsy. Hippocampus 1: 41-66.
74. Smith MD, Adams AC, Saunders GW, White HS, Wilcox KS,. (2007) Phenytoin- and carbamazepine-resistant spontaneous bursting in rat entorhinal cortex is blocked by retigabine in vitro. Epilepsy Res 74: 97-106. (Pubitemid 46654739)
75. Srivastava AK, White HS,. (2005) Retigabine decreases behavioural and electrographic seizures in the lamotrigine-resistant amygdala kindled rat model of pharmacoresistant epilepsy. Epilepsia 46 (Suppl. 8): 217-218.
76. Steriade M,. (2005) Sleep, epilepsy and thalamic reticular inhibitory neurons. Trends Nuerosci 28: 317-324. (Pubitemid 40775777)
77. Stratton SC, Large CH, Cox B, Davies G, Hagan RM,. (2003) Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. Epilepsy Res 53: 95-106. (Pubitemid 36170173)
78. Straub H, Kohling R, Hohling J, Rundfeldt C, Tuxhorn I, Ebner A, Wolf P, Pannek H, Speckmann E,. (2001) Effects of retigabine on rhythmic synchronous activity of human neocortical slices. Epilepsy Res 44: 155-165. (Pubitemid 32452225)
79. Sutula TP,. (2007) Experimental models of temporal lobe epilepsy: new insights from the study of kindling and synaptic reorganization. Epilepsia 31 (Suppl. 3): S45-S54.
80. Sutula TP, Hagen J, Pitkänen A,. (2003) Do epileptic seizures damage the brain? Curr Opin Neurol 16: 189-195. (Pubitemid 36521206)
81. Tober C, Rostock A, Rundfeldt C, Bartsch R,. (1996) D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 303: 163-169. (Pubitemid 26200668)
82. van Vliet EA, van SR, Edelbroek PM, da Silva FH, Wadman WJ, Gorter JA,. (2008) Development of tolerance to levetiracetam in rats with chronic epilepsy. Epilepsia 49: 1151-1159. (Pubitemid 351991387)
83. van Vliet EA, Edelbroek PM, Gorter JA,. (2010) Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats. Epilepsia 51: 362-370.
84. Volkers L, Rook MB, Das JH, Verbeek NE, Groenewegen WA, van Kempen MJ, Lindhout D, Koeleman BP,. (2009) Functional analysis of novel KCNQ2 mutations found in patients with Benign Familial Neonatal Convulsions. Neurosci Lett 462: 24-29.
85. Walton NY, Treiman DM,. (1988) Experimental secondarily generalized convulsive status epilepticus induced by D,L-homocysteine thiolactone. Epilepsy Res 2: 79-86. (Pubitemid 18063160)
86. Walton NY, Treiman DM,. (1992) Valproic acid treatment of experimental status epilepticus. Epilepsy Res 12: 199-205.
87. Walton NY, Jaing Q, Hyun B, Treiman DM,. (1996) Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. Epilepsy Res 24: 19-28. (Pubitemid 26191609)
88. White HS,. (2003) Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 44 (Suppl. 7): 2-8. (Pubitemid 37100022)
89. Wuttke TV, Jurkat-Rott K, Paulus W, Garncarek M, Lehmann-Horn F, Lerche H,. (2007) Peripheral nerve hyperexcitability due to dominant-negative KCNQ2 mutations. Neurology 69: 2045-2053. (Pubitemid 350175706)
90. Yonekawa WD, Kapetanovic IM, Kupferberg HJ,. (1995) The effects of anticonvulsant agents on 4-aminopyridine induced epileptiform activity in rat hippocampus in vitro. Epilepsy Res 20: 137-150.
91. Yus-Najera E, Munoz A, Salvador N, Jensen BS, Rasmussen HB, Defelipe J, Villarroel A,. (2003) Localization of KCNQ5 in the normal and epileptic human temporal neocortex and hippocampal formation. Neuroscience 120: 353-364. (Pubitemid 37288772)